Digital Asset DirectOxford Cannabinoid Technologies Holdings PLC
Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
May 24, 2023 10:59 AM Eastern Daylight Time
Video
News ReleaseMarketJar
One of the most stubborn, deadly cancers is pancreatic cancer. What if individualized mRNA vaccinations could support the immune system's defense? One of the deadliest forms of cancer around, pancreatic cancer is estimated to kill 88% of patients. It’s also one of the most recurrent cancers, with roughly 90% of patients experiencing a relapse within seven to nine months after surgery. Fortunately, a recent study of an mRNA vaccine for pancreatic cancer patients has provided a glimpse of hope. Scientists at Memorial Sloan Kettering (MSK) Cancer Center in New York just published the results of a small study that the group conducted in partnership with Germany’s BioNTech on pancreatic cancer patients over several years. The study used a pancreatic cancer mRNA vaccine tailored to each patient’s tumor to potentially help provoke an immune response. What’s revolutionary about the vaccines is that the German scientists tailored them to the mutated proteins on the surface of cancer cells instead of a mix of tumor and normal cells, which has been the method tried for decades. The cells were extracted from patients’ tumors by researchers at Memorial Sloan and sent to BioNTech, the company that created the highly-effective COVID-19 vaccine alongside Pfizer. Among the participants in the study, half of the patients’ immune systems learned how to recognize and fight off the cancer cells and showed no signs of relapse during the 18 months they were tracked. While promising, personalized mRNA cancer vaccines are still in their infancy and are too costly to be broadly used. Right now, regular cancer screening remains the best method for detecting cancers, however there are currently no screening tests for pancreatic cancer. Fortunately, that could soon change thanks to Mainz Biomed (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer Developing Early Screening Tests for Colon and Pancreatic Cancers On May 10, Mainz Biomed announced a partnership with Microba Life Sciences for the creation of PancAlert in addition to early colon cancer diagnostics. The technical characteristics of a novel pancreatic cancer screening test with DNA and microbiota indications should be enhanced. As part of the agreement, the two companies will conduct a pilot research project utilizing Microba’s proprietary metagenomic sequencing technology and bioinformatic tools in an effort to discover novel microbiome biomarkers to detect pancreatic cancer. The project, which is expected to run until late 2023, will use Microba's Community Profiler (MCP), a proprietary metagenomic platform technology that has proven to be a best-in-class research tool that can produce comprehensive and accurate species profiles of gastrointestinal samples. Mainz Biomed (NASDAQ:MYNZ) is also focused on commercializing its flagship product ColoAlert, a highly efficacious and simple-to-use detection test for colorectal cancer (CRC) that is already available in select international territories. In Q1 2023, the company also launched a corporate health program in Germany by integrating into BGM, a well-established corporate health program that provides services to employees at 48 of the 50 largest companies in Germany. On May 24, Mainz Biomed announced initial results from its colorectal cancer screening campaign with Zöller-Kipper GmbH through its BGM partnership. In April 2023, Zöller-Kipper selected ColoAlert for its corporate health program, which includes over 2,500 employees. According to the results, employees found the online patient portal easy-to-use and convenient and were able to readily access the portal, request a kit and securely receive results within five days. In order to process the ColoAlert PCR test kit, Mainz Biomed has added Eurofins GeLaMed to its network of lab partners. Eurofins GeLaMed is a division of the global laboratory company Eurofins Scientific, which conducts 450 million tests annually and has over 61,000 employees in 61 nations. Germany is home to four of its locations. Advancing Towards FDA Approval to Bring ColoAlert to the US Market Over the last few months, Mainz Biomed has continued to prepare for patient enrollment in its pivotal clinical trial for ColoAlert after successfully completing its pre-submission process with the FDA. ColoAlert will be examined in the FDA-registered trial "ReconAAsense" in order to obtain commercial approval in the United States. The company's business objective is to create scalable distribution across the nation once it receives approval through a cooperative partner program with regional and national laboratory service providers. Learn more about Mainz Biomed (NASDAQ:MYNZ) and its activities by clicking on this link. Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Mainz Biomed NV. Market Jar Media Inc. has or expects to receive from Mainz Biomed NV’s Digital Marketing Agency of Record (Native Ads Inc.) eighty nine thousand seven hundred sixty four USD for 12 days (9 business days). 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Mainz Biomed NV’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Mainz Biomed NV’s industry; (b) market opportunity; (c) Mainz Biomed NV’s business plans and strategies; (d) services that Mainz Biomed NV intends to offer; (e) Mainz Biomed NV’s milestone projections and targets; (f) Mainz Biomed NV’s expectations regarding receipt of approval for regulatory applications; (g) Mainz Biomed NV’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Mainz Biomed NV’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Mainz Biomed NV’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Mainz Biomed NV’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Mainz Biomed NV’s ability to enter into contractual arrangements with additional Pharmacies; (e) the accuracy of budgeted costs and expenditures; (f) Mainz Biomed NV’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Mainz Biomed NV to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Mainz Biomed NV’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Mainz Biomed NV’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Mainz Biomed NV’s business operations (e) Mainz Biomed NV may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, Mainz Biomed NV undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Mainz Biomed NV nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Mainz Biomed NV nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Mainz Biomed NV or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Mainz Biomed NV or such entities and are not necessarily indicative of future performance of Mainz Biomed NV or such entities. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com
May 24, 2023 09:00 AM Eastern Daylight Time
Image
Digital Asset DirectCreo Medical Group PLC
Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
May 23, 2023 11:15 AM Eastern Daylight Time
Video
News ReleasePathPresenter
PathPresenter, the global image sharing platform for pathology, today announced that their free public platform ( https://pathpresenter.net/ ) now has more than 50,000 registered users in 172 countries. Nearly 7,000 users have joined the pathology image sharing community in the past 12 months. Founded by dermatopathologist and digital pathology innovator, Dr. Rajendra Singh, PathPresenter has become the go-to, on-line community for pathologists, residents, fellows, scientists, and researchers who want to easily upload, view, and share whole slide images with their colleagues, as well as access curated image datasets from trusted experts. With over 100,000 hours of real-world usage, users have embraced PathPresenter’s best-in-class, lag-free imaging performance, super-easy sharing of images with colleagues (through URL links and/or QR codes), and the platform’s pathologist-built functionality. The viral popularity of PathPresenter public has helped spur the adoption of PathPresenter’s robust and secure enterprise platform at tier-one institutions, becoming one of the fastest growing digital pathology enterprise workflow platforms for use in clinical care, education, and research. The “instant familiarity” of the PathPresenter platform and brand – used by pathologists at almost every major hospital in the world – translates into higher rates of adoption and user enthusiasm among pathologists and therefore a higher return on investment for institutions implementing new digital pathology enterprise workflows. “Within 5 years, the majority of the world’s 1 billion glass slides produced each year will be digital. PathPresenter is building the roads and bridges to enable petabytes (soon to be exabytes) of digital pathology images to flow easily and securely within and between institutions to advance patient care, research, and pathology education,” said Patrick Myles, Chief Executive Officer of PathPresenter. “I would like to thank our community of 50,000+ PathPresenter users around the world for their unwavering support and their continued valuable input into the platform.” “It is the feedback from great colleagues from around the world that has helped us build practical workflow solutions to use digital pathology in all three pillars of our work: clinical care of our patients by providing accurate diagnosis with prognostic information, educating new pathologists, and accelerating research for better care of patients,” added PathPresenter founder, Dr. Rajendra Singh. “We will continue to work tirelessly with colleagues, institutions, and other vendors to ensure we can truly revolutionize our field and make it the center of personalized medicine.” About PathPresenter PathPresenter is the global image sharing platform for pathology. We are on a mission to help democratize access to the world’s pathology knowledge by connecting pathologists to the vast expertise of their colleagues globally and providing a practical platform to access and use best-in-class AI models. Founded in 2017 by dermatopathologist and digital pathology innovator, Dr. Rajendra Singh, PathPresenter has been adopted by 30+ tier one medical institutions for clinical care, education, and research, and has built a thriving community of 50,000+ users in 172 countries to easily view and share digital pathology images and knowledge. Learn more about pathpresenter.com. PathPresenter is available for primary diagnosis in the US during the COVID-19 public health emergency. In other countries, PathPresenter is intended for research and educational purposes only. Contact Details PathPresenter Cory Batenchuk - SVP of Operations +1 873-355-9913 cory@pathpresenter.com About PathPresenter PathPresenter is the global image sharing platform for pathology. We are on a mission to help democratize access to the world's pathology knowledge by connecting pathologists to the vast expertise of their colleagues globally and providing a practical platform to access and use best-in-class AI models. Founded in 2017 by dermatopathologist and digital pathology innovator, Dr. Rajendra Singh, PathPresenter has been adopted by 30+ tier one medical institutions for clinical care, education, and research, and has built a thriving community of 50,000+ users in 172 countries to easily view and share digital pathology images and knowledge. Learn more about pathpresenter.com. Contact Details Cory Batenchuk +1 873-355-9913 cory@pathpresenter.com Company Website https://pathpresenter.com
May 23, 2023 10:00 AM Eastern Daylight Time
News Release1606 Corp.
1606 Corp CEO Greg Lambrecht joins Proactive's Natalie Stoberman to share how the company's Brio Nutrition line of CBD products has been growing to meet enhanced demand. Lambrecht says since the acquisition of Brio, the company has secured significant orders from existing accounts and partnered with Cool Blue Distribution to access shelf space in over 800 CBD stores. Brio is currently fulfilling a $150,000 order with anticipation of further substantial orders in the near future. Lambrecht adds that to meet this growing demand, the company is ensuring a six-month inventory supply. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com
May 22, 2023 01:16 PM Eastern Daylight Time
Video
News ReleaseYourUpdateTV
Most people are aware of how poverty and structural inequality create challenges and barriers to accessing healthy food, education, jobs, health care and housing and how inflation is only making the crisis worse. Pet resources are no different. Many families are struggling to afford and access veterinary care, food and supplies for their beloved pets. More than 20 million pets live in poverty - three times as many pets live in poverty as enter shelters every year. This is a long overlooked national crisis exacerbated by inflation and the economy. Recently, Kitty Block, President and CEO of the Humane Society of the United States, participated in a nationwide satellite media tour to discuss the launch of the More Than a Pet campaign and how the organization is addressing the crisis. A video accompanying this announcement is available at: https://youtu.be/GdaZXktSjNI Over the past 20 years, the Humane Society of the United States has helped half a million pets and their families by providing veterinary care and supplies at no cost, keeping families and pets together in over 50 communities across the U.S. Without these services, families are often forced to make choices about sacrificing their own needs, even food and medications for themselves, to prioritize care for their pet. No family should ever have to make that choice. Since 2002, the Humane Society of United States’ Pets for Life and Rural Area Veterinary Services programs have been helping pet owners across the U.S. by providing food, supplies and services for their cats and dogs at no cost. It is critical to close the gap that exists for people and pets in underserved areas. With the new campaign called “More Than a Pet,” the HSUS is sounding an alarm about this crisis that is only getting worse. The Humane Society of the United States is offering these tips for people to support their communities: Advocate for keeping pets and their people together by signing the HSUS petition to close the pet equity gap. Your voice can make a big impact for all animals. Volunteer with the Humane Society of the United States’ Pets for Life and Rural Area Veterinary Services programs, which increase access to pet care for underserved communities. Donate pet food to your local shelter or pet food pantry. If you know of a neighbor in need, offer to help drive them to a veterinary appointment, foster their pet temporarily or provide a bag of their pet’s favorite food to help close the access to pet care gap. The HSUS is inviting the public to show their support for this campaign by sharing why their animal companion is #MoreThanAPet to them, at humanesociety.org/morethanapet. Campaign partner Smalls is donating a bowl of food for every photo shared, up to $1M, to pets and their families in need. Learn More and Get Involved About Kitty Block Kitty Block is the chief executive officer and president of the Humane Society of the United States and also chief executive officer of Humane Society International. She leads the nation's most effective animal protection organization in the fight for all animals. Block was named president and CEO of the Humane Society of the United States in January 2019, becoming the first woman to hold the position in the organization’s history. Block first joined the HSUS as a legal investigator in 1992 and was instrumental in bringing cruelties such as horse slaughter and the killing of dogs and cats for their fur in China to light. She led the HSUS’s efforts to secure protections for dolphins with successful litigation and landmark dolphin-safe tuna legislation. In addition, she was one of the architects of a successful lawsuit over commercial whaling brought against Japan by Australia in the International Court of Justice. She has served as an adviser to the White House on trade and the environment, and she has served multiple elected terms on the International Dolphin Conservation Agreement International Review Panel, which works with governments on monitoring violations of the agreement. Block received a law degree from The George Washington University in 1990 and a bachelor’s degree in communications and philosophy from the University of New Hampshire in 1986. She is a lifelong animal lover who helped her mother rescue and care for pets and other animals in need as a child. Block lives in Washington, D.C., with her husband and daughter, their street dog rescue, Lilly, and rescue cats, Misti and Storm Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com
May 22, 2023 10:15 AM Eastern Daylight Time
Video
News ReleaseUmbra Applied Technologies Group, Inc.
Umbra Applied Technologies Group, Inc. (OTC: UATG) announced today that it has reached an agreement with a strategic capital partner to support the growth of its subsidiary Ossifix Orthopedics. The private equity firm specializes in the medical field. The firm’s focus provides strategic growth capital and works with existing management to increase sales, benefiting both its own investors and value for all Ossifix shareholders. As part of the agreement, the new partner will become a nine percent stakeholder in Ossifix Orthopedics and will provide up to $2 million in funding capital. The firm will also provide additional value such as its investors and relationships to include an extensive portfolio of surgeons, medical facilities and knowledgebase, which will be utilized to further expand marketing and sales for Ossifix. Chief Financial Officer, Thomas Crom stated, “Although this reduces our ownership in Ossifix it dramatically increases Ossifx capability to move forward without any dilution to UATG’s shareholders. This Ossix transaction illustrates the creative ways UATG can fund its subsidiaries without diluting its current UATG shareholders. This type of funding is complex and time-consuming but illustrates Ossifix’s intrinsic value is now being recognized by others.”. This announcement on Friday came amid growing optimism among the Company’s executives that the traction the UAT Group conglomerate has gained in the first half of the year will exceed its expectations for the year; positioning it for a remarkable year. The investment into Ossifix contributes to the Company's consolidated growth initiatives which include augmenting existing product offerings and service capabilities of its subsidiaries as well as positioning infrastructure resources in support of planned expansion. UAT Group Chairman, Alex Umbra commented, “As always, UAT Group stands ready to support each of our subsidiaries, in any way necessary, as we capitalize on the values we create together. This new relationship will not only provide strategic capital but will continue to support growth objectives that will bolster shareholder value, streamline balance sheet debt and enable verticals to be realized sooner”. About Umbra Applied Technologies Group, Inc. The firm is located in Tampa, Florida and focuses on advanced technologies across many disciplines. UAT Group is a holding company with interests in both public and private companies during the early stages of development as well as growth stages of companies with a synergistic business model to UAT Group subsidiaries. For more information, visit: www.uatgroup.com Investor and Media Contact: info@uatgroup.com For more information about Ossifix Technologies, go here: https://ossifixtech.com/ NEITHER THE SECURITIES EXCHANGE COMMISSION NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE. Forward-Looking Information This news release may include "forward-looking statements" including forecasts, estimates, expectations, and objectives for future operations including but not limited to its ability to conclude a business combination with a third party, sale of assets, return of capital or initial public offering and a secondary listing on the OTC as a result of aforementioned and its ability to fund the exploration of its assets through the raising of equity or debt capital or through funding by a joint venture partner that are subject to a number of assumptions, risks, and uncertainties, many of which are beyond the control of Umbra Applied Technologies Group including but not limited to capital markets and securities risks and continued development success on technology. There can be and are no actual or implied guarantees that any of the above activities will be completed or completed on terms acceptable to the Company and its shareholders or approved by any regulatory authority having jurisdiction. Such forward-looking information represents management's best judgment based on information currently available. No forward-looking statement can be guaranteed, and actual future results may vary materially. Umbra Applied Technologies Group does not assume the obligation to update any forward-looking statement, except as required by applicable law. Contact Details Umbra Applied Technologies Group, Inc. info@uatgroup.com
May 19, 2023 08:00 AM Eastern Daylight Time
News ReleaseOxford Cannabinoid Technologies Holdings PLC
Oxford Cannabinoid Technologies Holdings PLC Clarissa Sowemimo-Coker tells Proactive's Stephen Gunnion that Medicines and Healthcare products Regulatory Agency (MHRA) approval of a phase 1 trial for its lead pain relief drug candidate, OCT461201, is a significant milestone for the company. Sowemimo-Coker said recruitment for the trial has already begun, with completion expected in the third quarter of 2023. The drug targets chemotherapy-induced peripheral neuropathy (CIPN) and has the potential for other indications like irritable bowel syndrome (IBS) and other neuropathy. The phase 1 trial focuses on safety and will pave the way for phase 2 trials in other indications, she added. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
May 18, 2023 07:21 AM Eastern Daylight Time
Video
News ReleaseMedinotec Inc
Medinotec CFO Pieter van Niekerk joins Natalie Stoberman from the Proactive studio to discuss how the company's reach in niche medical device manufacturing and distribution is growing in North America. Medinotec is a US-based company with a primary investment in DISA Medinotec, a South African medical device manufacturing and distribution company that is a global leader in tracheal non-occlusive airway dilation technology and medical device design, manufacture and distribution. van Niekerk says the company has taken recent steps to expand in the North American market by obtaining FDA approval for their unique non-occlusive device, as well as listing on the OTCQX market in March of 2023. van Niekerk adds that the company plans to diversify their medical devices through R&D projects, acquisitions, and partnerships, aiming to grow revenue streams and expand their product range. Contact Details Proactive United States Proactive United States +1 347-449-0879 action@proactiveinvestors.com
May 17, 2023 11:05 AM Eastern Daylight Time
Video
Contact Us
Pricing
About us
Features
News Hub
Terms of Use
Privacy Policy